Karly C Sourris

Summary

Country: Australia

Publications

  1. doi request reprint Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes
    Karly C Sourris
    Glycation and Diabetes Complications, Baker IDI Heart Research Institute, Melbourne, VIC 3004, Australia
    Free Radic Biol Med 52:716-23. 2012
  2. doi request reprint A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?
    Karly C Sourris
    JDRF Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, PO Box 6492 St Kilda Road Central, Melbourne, VIC 8008, Australia
    Am J Nephrol 30:323-35. 2009
  3. pmc Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy
    Karly C Sourris
    Glycation and Diabetes, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne 3004, Australia
    Exp Diabetes Res 2010:974681. 2010
  4. ncbi request reprint Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets
    Karly C Sourris
    Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Rd Central, Melbourne, 8008, Australia
    Curr Drug Targets 10:42-50. 2009
  5. doi request reprint Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
    K C Sourris
    JDRF Einstein Centre for Diabetes Complications, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne, Victoria, 8008, Australia
    Diabetologia 53:2442-51. 2010
  6. doi request reprint Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
    Adeline L Y Tan
    Juvenile Diabetes Research Foundation Einstein Centre for Diabetic Complications, Baker International Diabetes Institute Heart and Diabetes Research Institute, Melbourne, Victoria, Australia
    Am J Physiol Renal Physiol 298:F763-70. 2010
  7. doi request reprint Targeted reduction of advanced glycation improves renal function in obesity
    Brooke E Harcourt
    Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia
    Kidney Int 80:190-8. 2011
  8. pmc RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes
    Melinda T Coughlan
    Juvenile Diabetes Research Foundation Einstein Centre for Diabetes Complications, Division of Diabetes Complications, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
    J Am Soc Nephrol 20:742-52. 2009
  9. pmc Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man
    Melinda T Coughlan
    Glycation and Diabetes Complications, Baker IDI Heart and Diabetes Institute, St Kilda Rd Central, Melbourne, VIC 8008, Australia
    Am J Nephrol 34:347-55. 2011
  10. doi request reprint Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease
    Josephine M Forbes
    Glycation, Nutrition and Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Antioxid Redox Signal 19:331-43. 2013

Detail Information

Publications15

  1. doi request reprint Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes
    Karly C Sourris
    Glycation and Diabetes Complications, Baker IDI Heart Research Institute, Melbourne, VIC 3004, Australia
    Free Radic Biol Med 52:716-23. 2012
    ..Therefore CoQ10 supplementation may be renoprotective in type 2 diabetes, via preservation of mitochondrial function...
  2. doi request reprint A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?
    Karly C Sourris
    JDRF Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, PO Box 6492 St Kilda Road Central, Melbourne, VIC 8008, Australia
    Am J Nephrol 30:323-35. 2009
    ..These novel actions emphasise the importance of further examination of the advanced glycation pathway and in particular the diverse action of these agents in ameliorating the development of diabetic complications such as nephropathy...
  3. pmc Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy
    Karly C Sourris
    Glycation and Diabetes, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne 3004, Australia
    Exp Diabetes Res 2010:974681. 2010
    ..Advanced glycation end-products (AGEs) and their receptors are prominent contributors to diabetic kidney disease...
  4. ncbi request reprint Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets
    Karly C Sourris
    Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Rd Central, Melbourne, 8008, Australia
    Curr Drug Targets 10:42-50. 2009
    ..Modulation of AGE receptor expression is an important potential therapeutic approach worth consideration as a treatment for diabetic nephropathy and likely applicable to other vascular complications...
  5. doi request reprint Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
    K C Sourris
    JDRF Einstein Centre for Diabetes Complications, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne, Victoria, 8008, Australia
    Diabetologia 53:2442-51. 2010
    ..In this study, we examined whether the protective effects of RAGE blockade are exerted via modulation of the renal angiotensin II type 2 (AT2) receptor...
  6. doi request reprint Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
    Adeline L Y Tan
    Juvenile Diabetes Research Foundation Einstein Centre for Diabetic Complications, Baker International Diabetes Institute Heart and Diabetes Research Institute, Melbourne, Victoria, Australia
    Am J Physiol Renal Physiol 298:F763-70. 2010
    ..In the present study, diverse approaches to block the AGE-RAGE axis had disparate effects on DN, which has potential clinical implications for the way this axis should be targeted in humans...
  7. doi request reprint Targeted reduction of advanced glycation improves renal function in obesity
    Brooke E Harcourt
    Baker IDI Heart and Diabetes Research Institute, Melbourne, Victoria, Australia
    Kidney Int 80:190-8. 2011
    ..Thus, targeted reduction of the advanced glycation pathway improved renal function in obesity...
  8. pmc RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes
    Melinda T Coughlan
    Juvenile Diabetes Research Foundation Einstein Centre for Diabetes Complications, Division of Diabetes Complications, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
    J Am Soc Nephrol 20:742-52. 2009
    ....
  9. pmc Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man
    Melinda T Coughlan
    Glycation and Diabetes Complications, Baker IDI Heart and Diabetes Institute, St Kilda Rd Central, Melbourne, VIC 8008, Australia
    Am J Nephrol 34:347-55. 2011
    ..The aim of this study was to ascertain if the urinary excretion of proteins modified by advanced glycation can be used as biomarkers for albuminuria in individuals with type 1 or type 2 diabetes...
  10. doi request reprint Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease
    Josephine M Forbes
    Glycation, Nutrition and Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Antioxid Redox Signal 19:331-43. 2013
    ..To determine whether an abnormality in mitochondrial complex I per se is associated with development of renal disease, mice with a knockdown of the complex I gene, Ndufs6 were studied...
  11. ncbi request reprint Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway
    Vicki Thallas-Bonke
    JDRF Albert Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Medical Research Institute, P O Box 6492, St Kilda Rd, Central, Melbourne, Victoria, Australia
    Diabetes 57:460-9. 2008
    ..Since NADPH oxidase activation is closely linked to other putative pathways, its interaction with changes in protein kinase C (PKC) and increased advanced glycation was examined...
  12. doi request reprint Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy
    Sally A Penfold
    Division of Diabetes Complications, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
    Kidney Int 78:287-95. 2010
    ..These data show that ligands that activate RAGE present in the circulation of patients with type 2 diabetes and nephropathy are predominantly of high molecular weight...
  13. doi request reprint Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects
    Josephine M Forbes
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Amino Acids 46:321-6. 2014
    ..39; p < 0.01). In conclusion, in healthy humans, we show a cross-sectional association between advanced glycation end products and acute insulin secretion during glucose tolerance testing...
  14. doi request reprint Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?
    Karly C Sourris
    JDRF Albert Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Heart Research Institute, Melbourne, Victoria, Australia
    Ann N Y Acad Sci 1126:101-6. 2008
    ..To understand these novel mechanisms, further examination of the advanced glycation pathway and, in particular, the diverse action of these agents in ameliorating the development of diabetic complications is needed...
  15. pmc c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals
    Karly C Sourris
    Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
    Diabetes 58:1259-65. 2009
    ..Our study investigated potential relationships between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK) pathways-two pathways proposed as the link between CLAIS and insulin resistance...